These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also ...

The US biotech’s neurological drug candidate showed a reduction in disease progression of at least 50% and the company will ...

The small molecule drug arimoclomol (Miplyffa) has got the green light from the U.S. Food and Drug Administration (FDA) for ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met its primary endpoint. Insilico Medicine, a biotech company with offices in ...

The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, shortly after successfully completing a first phase 1 clinical trial. Nura Bio ...

She brings her global experience across multiple therapeutic areas to her current role leading operations at YPrime. In this position, Alison oversees project management and all teams responsible for ...

Lonza, a global leader in the pharmaceutical, biotech, and nutraceutical markets, has announced a significant expansion of its clinical manufacturing services at its small molecules site in Bend, ...